Bluebird Bio announces 25% workforce reduction, targets financial stability by 2025, and focuses on commercializing therapies LYFGENIA, ZYNTEGLO, and SKYSONA.

Bluebird Bio, a gene therapy company, has announced a restructuring plan that includes a 25% workforce reduction to achieve financial stability by the second half of 2025. The initiative aims for a 20% decrease in cash operating expenses and focuses on commercializing its therapies LYFGENIA, ZYNTEGLO, and SKYSONA. The FDA approved LYFGENIA in December 2023 for sickle cell disease, with about 40 patient starts expected in Q4 2024.

September 24, 2024
7 Articles